Lancet Oncology

Article	Citations
Health insurance system in Japan faces risk of politicisation	889
Navigating the complexity: reflections on the development of perioperative cancer treatments	639
Dual therapy in metastatic castration-resistant prostate cancer	578
US FDA proposes stronger laboratory test oversight	557
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	495
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	429
Toxicity assessment bias in the PACE-C trial – Authors' reply	419
New national cancer registry for France	411
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX	405
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus	387
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial	340
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomi	340
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial	333
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	328
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study	327
The future of precise cancer chronotherapeutics	316
Palliative radiotherapy for hepatic cancer pain	300
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply	296
SANO trial: innovations, risks, and unanswered questions	294
US Surgeon General calls for cancer warning labels on alcohol	292
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas	283
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	266
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study	250
Correction to Lancet Oncol 2021; 22: 1081–92	245
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	235

Olanzapine for chemotherapy-induced nausea and vomiting control	234
Study bolsters concerns about US FDA accelerated drug approvals	233
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	232
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	231
Survivorship after neoadjuvant chemotherapy	225
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	216
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy	216
SABR for operable stage I non-small-cell lung cancer: comparison to surgery	213
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	211
Correction to Lancet Oncol 2022; 23: 1124–26	207
Combination immunotherapy in chemotherapy in gastric cancer	207
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC	205
Use of artificial intelligence to enhance detection of nodal metastases	202
The silent malignant mesothelioma epidemic: a call to action	202
Patients with cancer in Louisiana denied fertility preservation cover	201
A new generation of comprehensive precision oncology trials	201
The GLOW trial in chronic lymphocytic leukaemia	199
Medical treatment for active breast cancer brain metastases	193
Precision medicine for children with cancer	193
Determining the optimal use of approved drugs in oncology	191
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised,	191
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	183
Concern for cancer drugs in USA–EU tariff war	182
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	180
IVLBCL mimicking VEXAS syndrome	179
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation	179
Italy to pass law on the right to be forgotten for cancer survivors	173
Innovation in gynaecological cancer: highlighting global disparities	170
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o	170
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t	169
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult	167
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply	167
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial	164
Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled,	161
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase	160
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm	159
Focus where it matters: turning insights into advocacy	158
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer	155
Syrian cancer patients regain treatment access in Türkiye	155
A growing vulvar mass in a post-menopausal woman	153
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	152
Cancer on the agenda during IAEA Director General's visit to Chile	149
Lung cancer rates highest among British Bangladeshi men	148
Balancing clinical benefit and social value: challenges in HTA assessments	147
Radiotherapy with genomic-adjusted radiation dose	145
Mantle cell lymphoma: is it time for risk-adapted treatment?	144
Radiotherapy with genomic-adjusted radiation dose	143
Correction to Lancet Oncol 2023; 24: e242	141
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire	140
Clearing the radiotherapy backlog: innovation to pave the way	140

2022 ASTRO annual meeting	136
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer	136
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra	135
A biobank perspective on use of tissue samples donated by trial participants	134
Common Sense Oncology: including everyone	134
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply	133
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer	133
Decentralised, point-of-care CAR-T for multiple myeloma	128
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?	128
Correction to Lancet Oncol 2020; 21: 699–709	127
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer	126
Effect of glycated haemoglobin A1c on the survival of patients with oral squamous cell carcinoma and diabetes: a multicentre, retrospective, database cohort study	124
ESMO Congress 2025	124
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA	121
Importance of clinical research for the UK's 10-year cancer plan	120
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup	119
Essential anticancer medicines for children: defining what matters most for Europe	118
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK	117
Radiotherapy and conflict: from disruption to expansion and hope	117
Oral contraceptives and risk of liver cancer	117
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group	114
Antimicrobial resistance in patients with haematological malignancies: a scoping review	113
Daratumumab maintenance in patients with myeloma	111
Challenges and prospects for cancer treatment in prison settings	109
WHO reports health service disruptions due to suspensions of aid	109
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer	106
Systemic therapy for brain metastases: a changing landscape	106
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations	105
India rolls out HPV vaccination	104
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study	104
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study	99
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial	98
Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer–Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa:	98
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo	98
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis	97
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit	97
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	96
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	96
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial	95
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update	95
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply	94
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti	94
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?	93
Correction to Lancet Oncol 2024; 25: e126–35	93
Internationally trained doctors in the USA	91
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting	88
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop	87
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?	87
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-co	83
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group	83
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	81
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care	81
The thin border between individual and collective ethics: the downside of GDPR	80
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply	79
Medical debt of people with cancer in the USA	79
Transforming cancer: behind the scenes at the Crick Institute	78
Correction to Lancet Oncol 2023; 24: 1181–95	78
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommen	77
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402)	77
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study	77
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, singl	76
Promoting cancer prevention through World Cancer Day in Nigeria	76
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply	75
ROAR trial: which treatment is effective after progression?	75
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial	74
Correction to Lancet Oncol 2021; 22: 1497–98	74
Endometrial cancer: the individual approach	74
Screening for breast cancer brain metastases	74
Managing immune checkpoint inhibition in transplant recipients	74
Mozambique takes on cancer burden challenges	74
Tumour response heterogeneity as a powerful independent predictor of treatment outcome in advanced lung adenocarcinoma: a retrospective analysis	74
Pembrolizumab monotherapy for advanced chordoma – Authors' reply	73
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry	73
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma	73
AACR Annual Meeting 2023	73
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label,	73
Study of the Veterans Affairs Health Care System highlights the impact of COVID-19 on cancer diagnoses in the USA	72
South Africa's new tobacco and e-cigarette control bill	72
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment	72
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose	71

6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting	71
A red patch on the palate	71
On a precipice: the UK's broken health-care system	70
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-lab	70
Pilot cancer programmes in Côte d'Ivoire, Kenya, and Zimbabwe	69
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply	69
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply	69
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia	68
Stereotactic ablative radiotherapy for primary kidney cancer	68
Anticipating the future of cancer care in Trump's America	68
Challenging cancer through poetry	68
American Lung Association calls for expanded insurance coverage for lung cancer screening	68
Qatar national cancer care and research: pioneering strategies for global health excellence	67
PSMA-PET research: addressing challenges and prospects – Authors' reply	67
Rwanda provides free treatment to all cancer patients	67
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease	66
US legislation might soon allow easier access to cancer medications	66
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic	66
Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer	66
Sharp increase in patients waiting months for urgent cancer treatment	66
Poor cancer care in Zimbabwe	66
Sharing a personal story behind brain cancer	65
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label,	62
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma	62
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-	62
US Clean Air in the firing line	62
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?	62
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean	61
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?	60
Sharing experiences and forming bonds at the Edinburgh Fringe	59
US cancer research might never recover from proposed Trump funding cuts	58
Delay to England's National Cancer Plan could cost lives	58
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges	58
Between the lines: an oncology diary no one assigned	58
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	57
US lawmakers call on Biden Administration to lower the price of enzalutamide	56
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	56
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised	56
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-02	55
Abemaciclib for malignant pleural mesothelioma – Authors' reply	55
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply	55
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases	55
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma – Authors' reply	55
Impact of integrated palliative care in acute and aggressive medical care for patients with advanced haematological malignancies: a retrospective matched case-control study	54
Quality control and childhood cancer medicines	54
Correction to Lancet Oncol 2016; 17: 484–95	54
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply	54
Correction to Lancet Oncol 2022; 23: 1297–307	54
Code of practice needed for samples donated by trial participants – Sponsor's reply	54
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study	54
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply	53
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply	53
HPV vaccine roll-out in Nigeria and Bangladesh	52
Problems with catch-up HPV vaccination after resumption of proactive recommendations	51
Correction to Lancet Oncol 2023; 24: e472–518	51
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma	51
Immunotherapy: balancing the risks and benefits	51
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial	50
Correction to Lancet Oncol 2023; 24: 91–106	50
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE	50
Essential medicines list in national cancer control plans: a secondary analysis from a global study	49
Correction to Lancet Oncol 2025; 26: 548–49	49
Management of locally advanced gastric cancer	49
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-a	49
New evidence for brain cancer risk after a single paediatric CT scan	49
WHO calls for investment in cancer prevention and care within a wider NCD strategy	49
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	48
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim resul	48
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study	48
The changing global landscape of national cancer control plans	48
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label	48
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, op	46
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed	46
Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial	46
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study	46
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	46
Indonesia and the Philippines take steps to control cancer	45
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial	45
Improved cancer coverage for firefighters in Western Australia	44
Correction to Lancet Oncol 2022; 23: 416–27	44
Correction to Lancet Oncol 2024; 25: 317–25	44
Cryptic metastatic calcification after radical nephrectomy in a patient with renal cell carcinoma	44
Horizon 2020 evaluation highlights benefit of cross-border research but points to areas for improvement	43
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	43
Correction to Lancet Oncol 2024; 25: 744–59	43
[18F]FDG-PET-guided radiotherapy for stage III non-small-cell lung cancer	42
Concerns regarding the AtTEnd trial in advanced endometrial carcinoma	42
Radiotherapy gaps and new frontiers in the Commonwealth	42
Reflections on the PEACE V–STORM trial	41
BrECADD and fertility: an ongoing concern	41
US mRNA cancer vaccine research faces an uncertain future	41
Cancer risk estimates for US EPA-approved alternative plastic-based fuel cause alarm	41
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?	41
BrECADD and fertility: an ongoing concern – Authors' reply	41
2025 ASCO Annual Meeting	41